免疫タンパク質診断検査市場：技術、免疫タンパク質タイプ、用途、エンドユーザー別-2025-2030年世界予測

免疫タンパク質診断検査市場は、2023年に88億1,000万米ドルと評価され、2024年には94億1,000万米ドルに達すると予測され、CAGR 6.92％で成長し、2030年には140億7,000万米ドルに達すると予測されています。

免疫タンパク質診断検査市場には、疾病の検出、モニタリング、管理のための免疫反応に関連するタンパク質の分析と利用が含まれます。これらの検査は、自己免疫疾患、感染症、がん、アレルギーなど様々な疾患の診断に不可欠です。これらの検査は個別化医療において重要な役割を果たし、正確な治療戦略を可能にし、患者の転帰を改善します。その用途は、病院、診断研究所、学術機関、研究機関など多岐にわたる。市場を牽引しているのは、慢性疾患の有病率の増加、技術の進歩、疾患の早期発見と予防への関心の高まりです。成長を促進する要因には、診断におけるAIと機械学習の統合、検査の精度と効率の向上などがあります。遠隔医療とデジタルヘルスケアプラットフォームの拡大は、遠隔患者モニタリングの新たな道を提供し、市場の需要をさらに促進しています。しかし、高度な診断ツールの高価格と規制上の課題が大きなハードルとなっています。さらに、免疫タンパク質の相互作用は複雑であるため、継続的な技術革新が必要であり、研究開発に多額の投資が必要となります。新興市場の動向は、コスト効率が高く、迅速で、携帯可能な診断ソリューションを開発することの重要性を浮き彫りにしています。バイオテクノロジー企業と研究機関との共同研究により、アッセイ開発やバイオマーカー探索に画期的な進展がもたらされ、検査の特異性や感度が向上する可能性があります。企業にとっては、検査プロセスの自動化とビッグデータ解析の統合に注力することで、納期を短縮し、検査結果からより深い考察を引き出すことで、競争力を高めることができます。最後に、診断検査の開発と展開における持続可能性と倫理的配慮は重要性を増しており、環境に優しく社会的責任のある事業を優先する企業にチャンスを提供します。既存の制約を乗り越えながらこれらのイノベーションを取り入れることは、免疫タンパク質診断検査業界において潜在的な成長機会を獲得し、長期的な市場プレゼンスを維持するのに役立ちます。

市場力学：急速に進化する免疫タンパク質診断検査市場の主要市場インサイトを公開

免疫タンパク質診断検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症および慢性疾患の罹患率と有病率の増加
  • 新興国における早期診断サービスの需要拡大
  • 診断検査の増加と化学発光アッセイの需要拡大
• 市場抑制要因
  • 免疫タンパク質診断検査のコスト高
• 市場機会
  • 免疫診断装置の技術的進歩、新しい自動化システムのイントロダクション
  • 病態特異的アッセイと検査の継続的開発
• 市場の課題
  • 免疫タンパク質診断検査の承認に関する複雑な規制の枠組み

ポーターの5つの力：免疫タンパク質診断検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：免疫タンパク質診断検査市場における外部からの影響の把握

外部マクロ環境要因は、免疫タンパク質診断検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析免疫タンパク質診断検査市場における競合情勢の把握

免疫タンパク質診断検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス免疫タンパク質診断検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、免疫タンパク質診断検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨免疫タンパク質診断検査市場における成功への道筋を描く

免疫タンパク質診断検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症および慢性疾患の発生率および有病率の増加
    • 新興国における早期診断サービスの需要増加
    • 診断検査の増加と化学発光アッセイの需要増加
  • 抑制要因
    • 免疫タンパク質診断検査の高コスト
  • 機会
    • 免疫診断機器の技術的進歩と新しい自動化システムのイントロダクション
    • 病状に応じたアッセイと検査の継続的な開発
  • 課題
    • 免疫タンパク質診断検査の承認に関する複雑な規制枠組み
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 免疫タンパク質診断検査市場：技術別

• 酵素免疫測定法
• 免疫蛍光アッセイ
• 放射免疫測定

第7章 免疫タンパク質診断検査市場免疫タンパク質の種類別

• C反応性タンパク質
• 補体系タンパク質
• 免疫グロブリン

第8章 免疫タンパク質診断検査市場：用途別

• アレルギー検査
• 自己免疫疾患検査
• 内分泌検査
• 感染症検査
• 腫瘍学検査
• 毒性試験

第9章 免疫タンパク質診断検査市場：エンドユーザー別

• 診断検査室
• 病院・クリニック
• 調査機関

第10章 南北アメリカの免疫タンパク質診断検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の免疫タンパク質診断検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの免疫タンパク質診断検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Abcam PLC
• Beckman Coulter Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• BioMerieux S.A.
• Calbiotech, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• DiaSys Diagnostic Systems GmbH
• Diazyme Laboratories Inc.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche AG
• Grifols, S.A.
• Luminex Corporation
• Miraca Holdings Inc.
• Ortho Clinical Diagnostics
• QIAGEN N.V.
• Randox Laboratories Ltd.
• SERVA Electrophoresis GmbH
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Werfen

LIST OF FIGURES

• FIGURE 1. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET RESEARCH PROCESS
• FIGURE 2. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ENZYME-LINKED IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY C-REACTIVE PROTEIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COMPLEMENT SYSTEM PROTEIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ALLERGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISEASE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ENDOCRINE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ONCOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 41. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 63. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 66. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 136. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 152. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 156. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IMMUNOPROTEIN TYPE, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 195. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Immunoprotein Diagnostic Testing Market was valued at USD 8.81 billion in 2023, expected to reach USD 9.41 billion in 2024, and is projected to grow at a CAGR of 6.92%, to USD 14.07 billion by 2030.

The immunoprotein diagnostic testing market encompasses the analysis and utilization of proteins related to the immune response for disease detection, monitoring, and management. These tests are vital in diagnosing various conditions such as autoimmune disorders, infectious diseases, cancers, and allergies. They play a crucial role in personalized medicine, enabling precise treatment strategies and improving patient outcomes. The application spans across hospitals, diagnostic laboratories, academic institutes, and research organizations. The market is driven by an increasing prevalence of chronic diseases, advancements in technology, and a heightened focus on early disease detection and prevention. Factors propelling growth include the integration of AI and machine learning in diagnostics, elevating the accuracy and efficiency of tests. The expansion of telemedicine and digital healthcare platforms offers new avenues for remote patient monitoring, further fueling market demand. However, the high cost of sophisticated diagnostic tools and regulatory challenges pose significant hurdles. Furthermore, the complexity of immunoprotein interactions requires continuous innovations, demanding substantial investment in research and development. Emerging trends highlight the importance of developing cost-effective, rapid, and portable diagnostic solutions to increase access in underserved regions, potentially broadening market reach. Collaborations between biotech firms and research institutions could yield breakthroughs in assay development and biomarker discovery, enhancing test specificity and sensitivity. For businesses, focusing on automation in testing processes and the integration of big data analytics could provide a competitive edge by reducing turnaround times and extracting deeper insights from test results. Lastly, sustainability and ethical considerations in the development and deployment of diagnostic tests are gaining importance, offering opportunities for companies that prioritize eco-friendly and socially responsible operations. Embracing these innovations while navigating existing limitations can help capture potential growth opportunities and sustain long-term market presence in the immunoprotein diagnostic testing industry.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunoprotein Diagnostic Testing Market

The Immunoprotein Diagnostic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in incidence and prevalence of infectious and chronic diseases
  • Growth in demand for early diagnostic services in emerging economies
  • Rise in diagnostic tests and growing demand for chemiluminescence assay
• Market Restraints
  • High cost of immunoprotein diagnostic tests
• Market Opportunities
  • Technological advancements in immunodiagnostic instruments and the introduction of novel automated systems
  • Ongoing development in the condition-specific assays and tests
• Market Challenges
  • Complex regulatory framework for the approval of immunoprotein diagnostic tests

Porter's Five Forces: A Strategic Tool for Navigating the Immunoprotein Diagnostic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunoprotein Diagnostic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunoprotein Diagnostic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunoprotein Diagnostic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunoprotein Diagnostic Testing Market

A detailed market share analysis in the Immunoprotein Diagnostic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunoprotein Diagnostic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunoprotein Diagnostic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunoprotein Diagnostic Testing Market

A strategic analysis of the Immunoprotein Diagnostic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunoprotein Diagnostic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, Beckman Coulter Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, BioMerieux S.A., Calbiotech, Inc., Danaher Corporation, DiaSorin S.p.A., DiaSys Diagnostic Systems GmbH, Diazyme Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, Grifols, S.A., Luminex Corporation, Miraca Holdings Inc., Ortho Clinical Diagnostics, QIAGEN N.V., Randox Laboratories Ltd., SERVA Electrophoresis GmbH, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.

Market Segmentation & Coverage

This research report categorizes the Immunoprotein Diagnostic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Enzyme-Linked Immunoassay, Immunofluorescence Assay, and Radioimmunoassay.
• Based on Immunoprotein Type, market is studied across C-reactive Protein, Complement System Protein, and Immunoglobulin.
• Based on Application, market is studied across Allergy Testing, Autoimmune Disease Testing, Endocrine Testing, Infectious Disease Testing, Oncology Testing, and Toxicology Testing.
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in incidence and prevalence of infectious and chronic diseases
    • 5.1.1.2. Growth in demand for early diagnostic services in emerging economies
    • 5.1.1.3. Rise in diagnostic tests and growing demand for chemiluminescence assay
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of immunoprotein diagnostic tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in immunodiagnostic instruments and the introduction of novel automated systems
    • 5.1.3.2. Ongoing development in the condition-specific assays and tests
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory framework for the approval of immunoprotein diagnostic tests
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immunoprotein Diagnostic Testing Market, by Technology

• 6.1. Introduction
• 6.2. Enzyme-Linked Immunoassay
• 6.3. Immunofluorescence Assay
• 6.4. Radioimmunoassay

7. Immunoprotein Diagnostic Testing Market, by Immunoprotein Type

• 7.1. Introduction
• 7.2. C-reactive Protein
• 7.3. Complement System Protein
• 7.4. Immunoglobulin

8. Immunoprotein Diagnostic Testing Market, by Application

• 8.1. Introduction
• 8.2. Allergy Testing
• 8.3. Autoimmune Disease Testing
• 8.4. Endocrine Testing
• 8.5. Infectious Disease Testing
• 8.6. Oncology Testing
• 8.7. Toxicology Testing

9. Immunoprotein Diagnostic Testing Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals & Clinics
• 9.4. Research Institutes

10. Americas Immunoprotein Diagnostic Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Immunoprotein Diagnostic Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Immunoprotein Diagnostic Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Abcam PLC
• 3. Beckman Coulter Inc.
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories Inc.
• 6. Bio-Techne Corporation
• 7. BioMerieux S.A.
• 8. Calbiotech, Inc.
• 9. Danaher Corporation
• 10. DiaSorin S.p.A.
• 11. DiaSys Diagnostic Systems GmbH
• 12. Diazyme Laboratories Inc.
• 13. Enzo Biochem Inc.
• 14. F. Hoffmann-La Roche AG
• 15. Grifols, S.A.
• 16. Luminex Corporation
• 17. Miraca Holdings Inc.
• 18. Ortho Clinical Diagnostics
• 19. QIAGEN N.V.
• 20. Randox Laboratories Ltd.
• 21. SERVA Electrophoresis GmbH
• 22. Siemens Healthineers
• 23. Sysmex Corporation
• 24. Thermo Fisher Scientific Inc.
• 25. Werfen